11/16/2009 10:27:44 AM
LONDON--(BUSINESS WIRE)--Immune Targeting Systems (ITS) Ltd, whose synthetic universal influenza-A vaccine enters clinical trials in 2010, today announced that Ken Powell has joined the board as non-executive Chairman. Ken was formerly CEO of Arrow Therapeutics which he led to a successful trade sale to Astra-Zeneca in 2007. The Company also announced the appointment of Dr. Campbell Bunce, formerly Development Director at Piramed, as R&D Director.
comments powered by